Lauxera Capital Partners
Also known as Lauxera, Lauxera Partners
Paris and San Francisco growth-equity and growth-buyout firm founded in 2020, investing €20–100M in commercial-stage healthtech companies; Lauxera Growth II closed at €520M in 2026.
- HEADQUARTERS
- Paris, France
- FOUNDED
- 2020
- OUTSIDE CAPITAL
- Yes
- TEAM LISTED
- 8 people
Focus
- STAGES
- GrowthBuyout
- SECTORS
- HealthTech
- ASSET MIX
- Private equityImpact
- GEOGRAPHY
- EuropeNorth America
Overview
Lauxera Capital Partners is a Paris portfolio management company, authorised by the AMF in February 2020, with a second office in the San Francisco area. It invests in healthtech companies that have significant revenue and have reached breakeven or early profitability, across medical devices, pharma and medtech services, digital health, healthcare data and software, and life science tools and diagnostics. Its second fund, Lauxera Growth II, closed at €520M in May 2026 and takes minority and majority positions of €20–50M, with a focus on helping European companies expand in the United States. Its first exit, OrganOx, was acquired by Terumo in October 2025.
Investment thesis
Invests when commercial execution is the main driver of value: healthtech companies addressing markets worth €500M+ a year that have reached breakeven or early profitability, with support for US market expansion.
PORTFOLIO (12)
- OrganOxNOTABLEHealthTech · Acquired
- Bridge to LifeHealthTech · since 2026
- GenePlanetHealthTech
- Antaros MedicalHealthTech
- AcandisHealthTech
- Natural CyclesHealthTech
- BioLaminaBiotech & Life Sciences
- LUMICKSBiotech & Life Sciences
- CaresyntaxHealthTech
- LifenHealthTech
- Synovo GroupSoftware & SaaS
- Matrix OneSoftware & SaaS
People
- Samuel LevyCo-founding Partner (Paris) · source
- Pierre MoustialCo-founding Partner (Paris) · source
- Alex SlackCo-founding Partner (San Francisco) · source
- Victor DecrionManaging Partner (Paris) · source
- Edoardo FracchiaPartner (Paris) · source
- Pauline RitterPrincipal (Paris) · source
- Anna YangCFO & Head of Operations (Paris) · source
- Lise de CourvilleHead of Investor Relations & ESG (Paris) · source
Links
Frequently asked questions
Lauxera Capital Partners is a private equity fund based in Paris, France, founded in 2020.
Lauxera Capital Partners invests directly in companies. Capital origin: third-party capital (fund LPs). Stated strategies include private equity and impact.
Lauxera Capital Partners invests at Growth and Buyout stages in HealthTech.
Lauxera Capital Partners's stated ticket size is €20M–€100M.
Key people at Lauxera Capital Partners include Samuel Levy (Co-founding Partner (Paris)), Pierre Moustial (Co-founding Partner (Paris)), Alex Slack (Co-founding Partner (San Francisco)) and Victor Decrion (Managing Partner (Paris)).
Lauxera Capital Partners's disclosed portfolio companies include OrganOx, Bridge to Life, GenePlanet, Antaros Medical, Acandis, Natural Cycles, BioLamina and LUMICKS, among others.
The most recent publicly reported investment by Lauxera Capital Partners is Bridge to Life ($110M Series C and debt financing (equity led by Soleus Capital with Lauxera)), announced in Aug 2026.